Q4 19 top-line growth was fuelled by the acceleration in sales for plasma-driven medicines and a sturdy show in the diagnostics division. Robust operational leverage combined with lower plasma procurement costs and financial expenses (due to debt refinancing) resulted in a significant jump in earnings. Given Grifols’ high exposure to China, 2019-nCoV could be a short-term dampener; nonetheless, the high unmet plasma demand in the region should bolster growth in the long term.
02 Mar 2020
Strong Q4; 2019-nCoV could weigh on performance in FY20
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q4; 2019-nCoV could weigh on performance in FY20
Grifols, S.A. Class A (GRF:WBO) | 0 0 1.0% | Mkt Cap: 14,874m
- Published:
02 Mar 2020 -
Author:
Rishabh Kochar -
Pages:
3
Q4 19 top-line growth was fuelled by the acceleration in sales for plasma-driven medicines and a sturdy show in the diagnostics division. Robust operational leverage combined with lower plasma procurement costs and financial expenses (due to debt refinancing) resulted in a significant jump in earnings. Given Grifols’ high exposure to China, 2019-nCoV could be a short-term dampener; nonetheless, the high unmet plasma demand in the region should bolster growth in the long term.